Regulatory Science, Innovation, and Health Equity Fellowship Established by Reagan-Udall Foundation for the FDA
Fellowship to focus on health equity, BeiGene announced as inaugural sponsor
(October 28, 2022) The Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results. By working directly on the priorities of the FDA and the Foundation, the fellowship will offer a unique opportunity for individuals to begin a career in regulatory science, while advancing health equity within the regulatory science workforce.
“We value diversity in our team and believe an inclusive workplace yields more meaningful outcomes—for our work, and for the FDA,” said Susan C. Winckler, RPh, Esq., Foundation CEO. “This fellowship program can provide an outstanding opportunity for professional development and is another step toward strengthening diversity within the field of regulatory science.”
The fellowship program’s inaugural sponsor, BeiGene, is a global biotechnology company that specializes in the development of drugs for cancer treatment. Additionally, they supported the FDA Foundation’s six-month pilot fellowship program in 2022.
Through the pilot, the Regulatory Science, Innovation and Health Equity Fellow focused on a Foundation project to aid in the development of medical products suitable for pregnant and lactating women, with an emphasis on integrating a health equity lens onto this important work.
The fellowship program will launch in early 2023. The Regulatory Science, Innovation, and Health Equity Fellowship program will help to facilitate diversity in the regulatory science field and individual career growth, providing fellows with the opportunity to build lasting professional relationships among FDA stakeholders.